Who Exports Insulin from India — 188 Suppliers Behind a $76.0M Market
India's insulin export market is supplied by 188 active exporters who collectively shipped $76.0M across 2,532 shipments. WOCKHARDT LIMITED leads with a 47.3% market share, followed by M. J. BIOPHARM PRIVATE LIMITED and M J BIOPHARM PRIVATE LIMITED. The top 5 suppliers together control 87.4% of total export value, reflecting a concentrated market structure.
Top Insulin Exporters from India — Ranked by Export Value
WOCKHARDT LIMITED is the leading insulin exporter from India, holding a 47.3% share of the $76.0M market across 2,532 shipments from 188 exporters. The top 5 suppliers — WOCKHARDT LIMITED, M. J. BIOPHARM PRIVATE LIMITED, M J BIOPHARM PRIVATE LIMITED, GLAND PHARMA LTD, ANGEL BIOGENICS PRIVATE LIMITED — collectively control 87.4% of total export value, indicating a highly concentrated market. Individual shares are: WOCKHARDT LIMITED (47.3%), M. J. BIOPHARM PRIVATE LIMITED (22.7%), M J BIOPHARM PRIVATE LIMITED (8.4%), GLAND PHARMA LTD (6.8%), ANGEL BIOGENICS PRIVATE LIMITED (2.2%).
Top Insulin Exporters from India
Ranked by export value · 188 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | WOCKHARDT LIMITED VALVEY 100IU/ML, 10ML VIAL (INSULIN GLARWINSULIN 30/70 100IU 5X3ML CARTRIDGEVALVEY 100IU/ML, 10ML VIAL | $35.9M | 25 | 47.3% |
| 2 | M. J. BIOPHARM PRIVATE LIMITED WINSULIN 30/70 100IU 5X3ML CARTRIDGEBIOSULIN 30/70 INSULIN INJ.BIPHASIC ISOPBIOSULIN N | $17.3M | 23 | 22.7% |
| 3 | M J BIOPHARM PRIVATE LIMITED VALVEY 100IU/ML, 10ML VIAL (INSULIN GLARWINSULIN 30/70 100IU 5X3ML CARTRIDGEVALVEY 100IU/ML, 10ML VIAL | $6.4M | 15 | 8.4% |
| 4 | GLAND PHARMA LTD | $5.2M | 4 | 6.8% |
| 5 | ANGEL BIOGENICS PRIVATE LIMITED | $1.7M | 4 | 2.2% |
| 6 | ORBIT LIFESCIENCE PVT. LTD. VALVEY 100IU/ML, 10ML VIAL (INSULIN GLARVALVEY 100IU/ML, 10ML VIALVALVEY 100IU/ML 10ML VIAL VLS | $1.7M | 1 | 2.2% |
| 7 | MODERN DRUG HOUSE | $1.1M | 2 | 1.5% |
| 8 | ORBIT LIFESCIENCE PRIVATE LIMITED VALVEY 100IU/ML, 10ML VIAL (INSULIN GLARVALVEY 100IU/ML, 10ML VIALVALVEY 100IU/ML 10ML VIAL VLS | $1.1M | 1 | 1.4% |
| 9 | TIMES MEDICAMENT PRIVATE LIMITED | $913.8K | 1 | 1.2% |
| 10 | SANOFI INDIA LIMITED | $640.4K | 2 | 0.8% |
| 11 | MEDICINE HOUSE WOSULIN 30/70 100IU/ML, 3ML CARTRIDGEWOSULIN R VIAL 100IU/ML 10ML (INSULIN IN | $571.4K | 2 | 0.8% |
| 12 | BIOCON BIOLOGICS INDIA LIMITED | $474.4K | 2 | 0.6% |
| 13 | GLAND PHARMA LIMITED | $419.2K | 5 | 0.6% |
| 14 | GENESYS BIOLOGICS PRIVATE LIMITED | $281.3K | 1 | 0.4% |
| 15 | JMB PHARMACEUTICALS PRIVATE LIMITED | $215.5K | 3 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Insulin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| WOCKHARDT LIMITED | Not Listed | Yes, valid until Feb | Yes | Not verified | WHO-GMP certificate valid until February 26, 2025; EU GMP compliance confirmed b |
| BIOCON BIOLOGICS INDIA LIMITED | Approved | Yes | Yes | Multiple | FDA approvals for biosimilars including Jobevne™ (bevacizumab-nwgd) in April 202 |
| BIOCON PHARMA LIMITED | Approved | Yes | Yes | Multiple | FDA approvals for Tofacitinib Extended-Release Tablets in November 2025; EU GMP |
| GLAND PHARMA LIMITED | Approved | Yes | Yes | Multiple | FDA approvals for various injectable products; WHO-GMP and EU GMP certifications |
| SANOFI INDIA LIMITED | Approved | Yes | Yes | Multiple | FDA approvals for various pharmaceutical products; WHO-GMP and EU GMP certificat |
| GENESYS BIOLOGICS PRIVATE LIMITED | Not Listed | Yes | Yes | Not verified | WHO-GMP and EU GMP certifications confirmed. |
| JMB PHARMACEUTICALS PRIVATE LIMITED | Not Listed | Yes | Yes | Not verified | WHO-GMP and EU GMP certifications confirmed. |
| M. J. BIOPHARM PRIVATE LIMITED | Not Listed | Yes | Yes | Not verified | WHO-GMP and EU GMP certifications confirmed. |
TransData Nexus reviewed the regulatory standing of 8 leading Insulin exporters from India. 4 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Insulin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs), including those used in insulin manufacturing. The city's pharmaceutical ecosystem is bolstered by the presence of numerous WHO-GMP-certified facilities, contributing significantly to India's capacity to meet global insulin demand. Companies like Neuland Laboratories, headquartered in Hyderabad, specialize in the production of APIs and advanced intermediates, playing a crucial role in the insulin supply chain.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts a concentration of manufacturing units dedicated to producing finished dosage forms of insulin. Notably, Novo Nordisk, in partnership with Torrent Pharmaceuticals, expanded an insulin manufacturing facility at Torrent’s Indrad site in Gujarat, enhancing the region's capacity for insulin formulation and packaging.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products, including insulin. This region's well-developed port infrastructure facilitates efficient international distribution. Companies like Wockhardt Limited, headquartered in Mumbai, have leveraged this strategic location to become leading exporters of insulin, accounting for a significant share of India's insulin exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, partly due to favorable tax incentives. This zone attracts numerous pharmaceutical companies, contributing to the production of various drugs, including insulin. The region's growth is supported by government initiatives aimed at boosting domestic manufacturing and reducing import dependence.
5Sourcing Recommendations
- Diversify Supplier Base: While Wockhardt Limited is a major supplier, accounting for 47.3% of insulin exports, it's prudent to engage with other significant exporters like M. J. Biopharm Private Limited and Gland Pharma Ltd to mitigate supply chain risks.
- Leverage Regional Strengths: Consider sourcing from clusters specializing in specific aspects of insulin production. For instance, Hyderabad for APIs and Ahmedabad-Vadodara for formulations, to optimize quality and cost-effectiveness.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards, such as WHO-GMP, to maintain product integrity and facilitate smoother export processes.
- Stay Informed on Policy Changes: Keep abreast of government initiatives and tax incentives in regions like Baddi-Nalagarh, which may offer cost advantages and influence sourcing decisions.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Insulin exporters from India
Wockhardt Limited — Wockhardt to produce, supply Sputnik V, Sputnik Light Covid vaccine
Wockhardt signed an agreement with Dubai-based Enso Healthcare and Russian firm Human Vaccine LLC to contract manufacture the Sputnik V and Sputnik Light vaccines in India. - IMPACT: This collaboration may divert resources from insulin production, potentially affecting export volumes.
Impact: This collaboration may divert resources from insulin production, potentially affecting export volumes.
Common Questions — Insulin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which insulin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, WOCKHARDT LIMITED leads with 454 recorded shipments worth $35.9M. M. J. BIOPHARM PRIVATE LIMITED (303 shipments) and M J BIOPHARM PRIVATE LIMITED (75 shipments) are also established high-volume exporters.
Q How many insulin manufacturers are there in India?
India has 188 active insulin exporters with a combined export market of $76.0M across 2,532 shipments to 111 countries. The top 5 suppliers hold 87.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for insulin from India?
Average FOB unit price: $15.38 per unit, ranging from $0.00 to $3157.05. Average shipment value: $30.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 188 verified Indian exporters of Insulin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,532 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 111 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,532 Verified Shipments
188 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists